RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancerONCY will have 13 years of FDA marketing exclusivity from the date of FDA approval for pelareorep in breast cancer for example. And another 13 year of market exclusivity for pancreatic cancer, as another example, ...and so on for subsequent FDA approvals for pelareorep in subsequent indications.